Inovio launches Ph1 study of Hep C vaccine

Inovio Pharmaceuticals (NSDQ:INO) and its partner, GeneOne Life Science (KSE:011000), said today that the companies have dosed the first patient in a Phase I study designed to test a preventive vaccine against hepatitis C infection.

The companies plan to recruit 24 study participants to evaluate Inovio’s GLS-6150 candidate. Participants will include people who have a sustained virologic response following treatment for Hep. C, as well as healthy controls. They are slated to receive one of two doses of vaccine, administered intra-dermally and followed by electroporation with Inovio’s Cellectra device.

Get the full story at our sister site, Drug Delivery Business News.

The post Inovio launches Ph1 study of Hep C vaccine appeared first on MassDevice.

Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US

Otsuka Pharmaceutical (TYO:4578) said today it inked a collaborative deal with health management group Magellan Health to distribute its drug-device combo Abilify Mycite in the US.

The Tokyo-based pharmaceutical company touted the Abilify Mycite system as the first FDA-approved drug-device combo designed to track drug ingestion, and said that the tracking data will be integrated into Magellan Health’s mental health provider network.

Read the whole story on our sister site, Drug Delivery Business News

The post Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US appeared first on MassDevice.

Medtronic launches In.Pact Admiral drug-coated balloon in Japan

Medtech titan Medtronic (NYSE:MDT) said today that it launched its In.Pact Admiral drug-coated balloon in Japan.

The company won approval and reimbursement for its device last year from the Japanese Ministry of Health, Labor and Welfare for the treatment of peripheral artery disease in the upper leg.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic launches In.Pact Admiral drug-coated balloon in Japan appeared first on MassDevice.

Novocure inks collaboration for pivotal pancreatic cancer trial

Novocure (NSDQ:NVCR) and US Oncology Research said today that the groups are collaborating on a phase III pivotal trial designed to test Novocure’s Tumor Treating Fields with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer.

Using a network of community-based oncology practices, US Oncology Research plans to open 10 clinical trial sites to enroll patients in Novocure’s Panova-3 trial, the companies reported.

Get the full story at our sister site, Drug Delivery Business News.

The post Novocure inks collaboration for pivotal pancreatic cancer trial appeared first on MassDevice.

Capillary Biomedical raises $3m to support insulin infusion tech

Capillary Biomedical said today that it raised $2.9 million in a seed funding round to support regulatory filings and the launch of its insulin infusion technology.

The company is gearing up for clinical trials to support a 510(k) filing and hopes to bring its SteadiSet infusion set to the market in 2019.

Get the full story at our sister site, Drug Delivery Business News.

The post Capillary Biomedical raises $3m to support insulin infusion tech appeared first on MassDevice.

Valeritas tops sales, earnings estimates in Q2

Valeritas (NSDQ:VLRX) topped sales and earnings expectations on Wall Street this week with its second-quarter financial results.

The Bridgewater, N.J.-based company posted a net loss of -$10.9 million on sales of $6.5 million for the three months ended June 30, for sales growth of 36% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas tops sales, earnings estimates in Q2 appeared first on MassDevice.

Ocular Therapeutix beats The Street with Q2 results

Shares in Ocular Therapeutix (NSDQ:OCUL) rose this week after the company topped expectations on Wall Street with its second-quarter financial results.

The Bedford, Mass.-based company posted a net loss of -$13.8 million on sales of $648,000 for the three months ended June 30, representing sales growth of 48% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Ocular Therapeutix beats The Street with Q2 results appeared first on MassDevice.

Tandem reels in $115m from public offering

Tandem Diabetes Care (NSDQ:TNDM) said today that it raised roughly $115 million from an underwritten public offering.

The San Diego, Calif.-based company offered 3,508,770 shares of its common stock at $28.50 apiece. Underwriters fully exercised an option to buy 526,315 additional shares of common stock, Tandem noted.

Get the full story at our sister site, Drug Delivery Business News.

The post Tandem reels in $115m from public offering appeared first on MassDevice.

Report: Smiths may abandon talks of merger with ICU Medical

Smiths Group (LON:SMIN) may walk away from talks of a $9 billion merger of its healthcare division with ICU Medical (NSDQ:ICUI), Sky News reported this week.

The two groups began talks more than two months ago, but Smiths is reportedly leaning towards a decision to abandon negotiations.

Get the full story at our sister site, Drug Delivery Business News.

The post Report: Smiths may abandon talks of merger with ICU Medical appeared first on MassDevice.

Mylan lowers outlook after Q2 earnings, sales miss estimates

Shares in Mylan (NSDQ:MYL) fell today after the pharmaceutical company missed expectations on Wall Street with its second-quarter financial results.

The Canonsburg, Penn.-based company posted profits of $37.5 million, or 7¢ per share, on sales of $2.8 billion for the three months ended June 30, representing a bottom-line loss of -87.4% on a sales loss of 5% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Mylan lowers outlook after Q2 earnings, sales miss estimates appeared first on MassDevice.